Abstract
In two independent trials 10 and 12 healthy volunteers received the novel intravenous immunoglobulin (IVIG) preparations BT 511 and BT 507, respectively. BT 511 contains 5 g human plasma proteins per 100 ml, more than 95% of which are immunoglobulins of the G class (IgG). BT 507 contains in addition 61 IU antibody against hepatitis B surface antigen (anti-HBs)·ml−1. In trial I volunteers received 4.0 ml/kg (n+4) and 8.0 ml·kg−1 (n+6) BT 511 to study the tolerability and the magnitude of the increase in immunoglobulins in plasma as well as their decline over 1 month. After administration of the lower dose, plasma IgG increased from 10.7 to 14.7 g·l−1 directly after the infusion. Following the 8.0 ml·kg−1 dose a more pronounced increase from 12.4 to 21.2 g·l−1 was observed. No adverse events occurred. After 1 month IgG concentrations had almost reached baseline values at 12.2 g·l−1 in the 4.0 ml·kg−1 group, but were still significantly increased at 15.2 g·l−1 after the high dose. There was a linear correlation between the maximal IgG plasma concentration and the subsequent decline of IgG during the 29-day observation period. After administration of BT 507 maximal anti-HBs concentrations of 1778 mU·ml−1 occurred 1.4 h after termination of the infusion. The terminal elimination half-life was 22.4 days, and total clearance and volume of distribution were determined to be 0.122 ml·min−1 and 5.41, respectively. The pharmacokinetic parameters calculated for anti-HBs as an indicator of IgG were in accordance with the pharmacokinetic behaviour of native IgG.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hammarström L, Gardulf A, Hammarström V, Janson A, Lindberg K (1994) Systemic and topical immunoglobulin treatment in immunocompromised patients. Immuno Rev 139:43–70
Cohn EJ, Gurd FRN, Suigenor DM, Barnes BA, Brown RK, Deronaux G, Gillespie JM, Kahnt FW, Lever WF, Lin CH, Mittelmann D, Mouton RF, Schmid K, Uroma E (1950) A system for the separation of the components of human blood quantitative procedure for the separation of the protein components of human plasma. J Am Chem Soc 72:465–470
Jungi TW, Santer M, Lerch PG, Barandun S (1986) Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. Vox Sang 51:18–26
Morell A, Skavril F (1980) Struktur und biologische Eigenschaften von Immunglobulinen. II. Eigenschaften von γ-Globulin-Präparaten Schweiz Med Wochenschr 110:80–85
Barandun S, Castel V, Makula MF, Morell A, Plan R, Skavril F (1975) Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application. Vox Sang 28:157–175
Commission of the EC (1991) Validation of virus removal and inactivation procedures. III/8115/89-EN-Final 1991 In: Feiden K ed(1994) Arzneimittelprüfrichtlinien. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Morell A, Skavril F, Barandun S (1975) IgG-Subklassen der menschlichen Immunglobuline, 1st edn. Karger, Basel
Mushahwar IK, Dienstag JL, Polesky HF, McGrath LC, Decker RH, Overby LR (1981) Interpretation of various serological profiles of hepatitis B virus infection. Am J Clin Pathol 76:773–777
Heinzel G, Wolosczak R, Thomann P (1993) TOPFIT. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Fischer, Stuttgart
Hagenbeek A, Brummelhuis HGJ, Donkers A, Dumas AM, ten Haaft A, Schaap BJP, Sizoo W, Löwenberg B (1987) Rapid clearance of cytomegalovirus IgG after repeated intravenous infusion of human immunoglobulin in allogenic bone marrow transplant recipients. J Infect Dis 155:897–902
Shibata Y, Baba M, Kuniyuki M (1983) Studies on the retention of passively transferred antibodies in man. II. Antibody activity in the blood after intravenous or intramuscular administration of anti-HBs human immunoglobulin. Vox Sang 45:77–82
Rossing N (1978) Intra- and extravascular distribution of albumin and immunoglobulin in man. Lymphology 11:138–142
Waldmann TA, Strober W (1969) Metabolism of immunoglobulins. Progr Allergy 13:1–110
Glöckner WM (1984) Kinetik von Immunglobulin G nach intravenöser und intramuskulärer Applikation. In: Kornhuber B (ed) Patient — Infektion — Immunoglobulin. Springer, Berlin Heidelberg New York, pp 33–38
Ein D, Waldmann T (1969) Metabolic studies of a heavy chain disease protein. J Immunol 103:345–348
Fahey JL, Robinson AG (1963) Factors controlling serum γ-globulin concentration. J Exp Med 118:845–868
Gratwohl A, Doran JE, Bachmann P, Scherz R, Späth P, Baumgartner C, Perret B, Berger C, Nissen C, Tichelli A, Speck B, Morell A (1991) Serum concentrations of immunoglobulins and anitbody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmunoglobulin. Bone Marrow Transp 8:275–282
Reusser P, Osterwalder B, Gratama JW, The TH, Gratwohl A, Speck B (1989) Kinetics of cytomegalovirus IgG antibody following infusion of a hyperimmune globulin preparation in allogenic marrow transplant recipients. Bone Marrow Transp 4:267–272
Schiff RI, Rudd C, Johnson R, Buckley RH (1984) Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage. Clin Immunol Immunopathol 31:13–23
Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, Wedgwood RJ (1988) The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 112:634–640
Solomon A, Waldmann TA, Fahey JL (1963) Metabolism of normal 6.6 S γ-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma. J Lab Clin Med 62:1–17
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thürmann, P.A., Sonnenburg-Chatzopoulos, C. & Lissner, R. Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation. Eur J Clin Pharmacol 49, 237–242 (1995). https://doi.org/10.1007/BF00192385
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00192385